Our website uses cookies. We use cookies to remember settings and to help provide you with the best experience we can. We also use cookies to continuously improve our website by compiling visitor statistics. Read more about cookies

Roger Brüggemann

Roger Brüggemann

Researcher
 
 
  • Comment on

    • nov. 2022
    • Beatrijs, Mertens, et al
    • Journal of Antimicrobial Chemotherapy
  • Liposomal amphotericin B-the past

    • nov. 2022
    • R. J., Brüggemann, et al
    • Journal of Antimicrobial Chemotherapy
  • Risk-proportionate approach to paediatric clinical trials

    • okt. 2022
    • Mandy, Wan, et al
    • Clinical Trials
  • Tackling the emerging threat of antifungal resistance to human health

    • sep. 2022
    • Matthew C., Fisher, et al
    • Nature Reviews Microbiology
  • Ciprofloxacin Pharmacokinetics After Oral and Intravenous Administration in (Morbidly) Obese and Non-obese Individuals

    • aug. 2022
    • Koen P., van Rhee, et al
    • Clinical Pharmacokinetics
View all publications